In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, ...

A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...

LOS ANGELES, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) ...

Faith writes guides, how-tos, and roundups on the latest Android games and apps for Android Police. You'll find her writing about the newest free-to-play game to hit Android or discussing her paranoia ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may provide false low glucose readings. Hundreds of adverse events and seven ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class ...